Correlation risk analysis of serum Amyloid A, Procalcitonin and IFN-β2 in adverse outcomes of acute pancreatitis
Serum Amyloid A, Procalcitonin and IFN-β2 levels in acute pancreatitis
Abstract
[Objective] To investigate the relationships between the severity and prognosis of individuals with acute pancreatitis (AP) and the levels of serum amyloid A, procalcitonin, and interferon-β2 (IFN-β2).
[Methods] 224 AP patients who were admitted to our hospital between February 2022 and February 2024 were chosen to serve as research participants. According to the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, the patients were divided into a mild AP group (140 patients) and a severe AP group (84 patients). The levels of serum amyloid A, CRP, procalcitonin and IFN-β2 in the two groups were compared, and the relationships between the levels of serum amyloid A, CRP, procalcitonin and IFN-β2 and the severity of the disease were analyzed via Spearman correlation. The factors affecting the prognosis of AP patients were examined using binary logistic regression, receiver operating characteristic (ROC) curves were used to evaluate the prognostic significance of serum amyloid A, CRP, procalcitonin, and IFN-β2 for the prognosis of AP patients.
[Results] The levels of serum amyloid A, CRP, procalcitonin and IFN-β2 in the mild AP group were significantly lower than those in the severe AP group (P<0.05). The severity of AP was favorably connected with serum amyloid A, CRP, procalcitonin, and IFN-β2 levels (r=0.774, 0.678, 0.830, 0.584, P<0.05). After 28 days of follow-up, among 224 AP patients, 64 patients (28.57%) had poor prognoses, including 20 patients (8.93%) with respiratory insufficiency, 24 patients (10.71%) with hypocalcemia, and 20 patients (8.93%) who died. The severe AP group also had a higher overall incidence of poor prognosis than the moderate AP group (P<0.05). AP patients' poor prognosis was revealed to be influenced by the APACHE II score and blood levels of serum amyloid A, CRP, procalcitonin, and IFN-β2 (P<0.05). According to the ROC curve study, the blood serum amyloid A, CRP, procalcitonin, and IFN-β2 levels' areas under the curve for predicting a poor AP prognosis were 0.859, 0.851, 0.811, and 0.802, all of which had some predictive value.
[Conclusion] serum amyloid A, CRP, procalcitonin, and IFN-β2 levels show a strong prognostic value for AP patients' prognosis and are positively connected with the severity of AP.
References
2.Song Y, Lee SH. Recent Treatment Strategies for Acute Pancreatitis. J Clin Med. 2024 Feb 8;13(4):978. doi: 10.3390/jcm13040978. PMID: 38398290; PMCID: PMC10889262.
3.Shuanglian Y, Huiling Z, Xunting L, Yifang D, Yufen L, Shanshan X, Lijuan S, Yunpeng L. Establishment and validation of early prediction model for hypertriglyceridemic severe acute pancreatitis. Lipids Health Dis. 2023 Dec 8;22(1):218. doi: 10.1186/s12944-023-01984-z. PMID: 38066493; PMCID: PMC10709974.
4.Tarján D, Szalai E, Lipp M, Verbói M, Kói T, Erőss B, Teutsch B, Faluhelyi N, Hegyi P, Mikó A. Persistently High Procalcitonin and C-Reactive Protein Are Good Predictors of Infection in Acute Necrotizing Pancreatitis: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2024 Jan 20;25(2):1273. doi: 10.3390/ijms25021273. PMID: 38279274; PMCID: PMC10816999.
5.Yin Y, Wei N, Zheng Z, Liang H. Relationship between apoA-I, chemerin, Procalcitonin and severity of hyperlipidemia-induced acute pancreatitis. J Pak Med Assoc. 2022 Jun;72(6):1201-1204. doi: 10.47391/JPMA.3700. PMID: 35751336.
6.Alberti P, Pando E, Mata R, Cirera A, Fernandes N, Hidalgo N, Gomez-Jurado MJ, Vidal L, Dopazo C, Blanco L, Gómez C, Caralt M, Balsells J, Charco R. The role of procalcitonin as a prognostic factor for acute cholangitis and infections in acute pancreatitis: a prospective cohort study from a European single center. HPB (Oxford). 2022 Jun;24(6):875-884. doi: 10.1016/j.hpb.2021.10.016. Epub 2021 Nov 1. PMID: 34802942.
7.Ugurlu ET, Yurekli UF. The effect of procalcitonin and immature granulocyte ratio in predicting the development of acute necrotizing pancreatitis: evidence from 582 cases. Eur Rev Med Pharmacol Sci. 2022 Oct;26(20):7514-7521. doi: 10.26355/eurrev_202210_30022. PMID: 36314322.
8.He Q, Ding J, He S, Yu Y, Chen X, Li D, Chen F. The predictive value of procalcitonin combined with C-reactive protein and D dimer in moderately severe and severe acute pancreatitis. Eur J Gastroenterol Hepatol. 2022 Jul 1;34(7):744-750. doi: 10.1097/MEG.0000000000002376. Epub 2022 Apr 5. PMID: 35412505; PMCID: PMC9148668.
9.Cho IR, Do MY, Han SY, Jang SI, Cho JH. Comparison of Interleukin-6, C-Reactive Protein, Procalcitonin, and the Computed Tomography Severity Index for Early Prediction of Severity of Acute Pancreatitis. Gut Liver. 2023 Jul 15;17(4):629-637. doi: 10.5009/gnl220356. Epub 2023 Feb 15. PMID: 36789576; PMCID: PMC10352050.
10.Zhou H, Li W, Yang S, Yang H, Cai Y. Prediction of acute pancreatitis severity using NLR, procalcitonin, and CT severity score: A retrospective study. Medicine (Baltimore). 2025 Jul 4;104(27):e43055. doi: 10.1097/MD.0000000000043055. PMID: 40629608; PMCID: PMC12237365.
11.Padula D, Mauro A, Maggioni P, Kurihara H, Di Sabatino A, Anderloni A. Practical approach to acute pancreatitis: from diagnosis to the management of complications. Intern Emerg Med. 2024 Nov;19(8):2091-2104. doi: 10.1007/s11739-024-03666-9. Epub 2024 Jun 8. PMID: 38850357.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
13.Ebik B, Kacmaz H, Tuncel ET, Arpa M, Ucmak F, Kaya M. What does the Procalcitonin Level Tell us in Patients with Acute Pancreatitis? J Coll Physicians Surg Pak. 2022 Oct;32(10):1272-1277. doi: 10.29271/jcpsp.2022.10.1272. PMID: 36205270.
14.Zhu QY, Li RM, Zhu YP, Hao DL, Liu Y, Yu J, Yang X, Zhang YS, Lin TJ, Yan X, Zuo JX, Pan XT. Early Predictors of Infected Pancreatic Necrosis in Severe Acute Pancreatitis: Implications of Neutrophil to Lymphocyte Ratio, Blood Procalcitonin Concentration, and Modified CT Severity Index. Dig Dis. 2023;41(4):677-684. doi: 10.1159/000529366. Epub 2023 Mar 30. PMID: 36996800.
15.Mann BK, Bhandohal JS, Kalha I, Fox K, Jean B. Relevance of Procalcitonin Levels as a Marker of Severity and Predictor of Mortality, Initiation and Duration of Antibiotics in Patients Admitted with Acute Pancreatitis: A Retrospective Cohort Study. Clin Exp Gastroenterol. 2024 Feb 9;17:31-39. doi: 10.2147/CEG.S453345. PMID: 38352170; PMCID: PMC10863456.
16.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
17.Jakkampudi A, Sarkar P, Unnisa M, Patil A, Koutarapu C, Jaggaiahgari S, Naik P, Sarkar S, Prasanna A, Chintaluri S, Reddy DN, Beedu SR, Talukdar R. Kynurenine pathway alteration in acute pancreatitis and its role as a biomarker of infected necrosis. Pancreatology. 2023 Sep;23(6):589-600. doi: 10.1016/j.pan.2023.07.003. Epub 2023 Jul 5. PMID: 37438173.
18.Mir BA, Majeed T, Chauhan A. Procalcitonin-guided use of antibiotics in acute pancreatitis. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1073. doi: 10.1016/S2468-1253(22)00271-0. PMID: 36370735.
19.Samanta J, Dhar J. Procalcitonin-guided use of antibiotics in acute pancreatitis. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1073-1074. doi: 10.1016/S2468-1253(22)00272-2. PMID: 36370734.
20.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
21.Badia JM, Amador S, González-Sánchez C, Rubio-Pérez I, Manuel-Vázquez A, Juvany M, Membrilla E, Balibrea JM, Guirao X. Appropriate Use of Antibiotics in Acute Pancreatitis: A Scoping Review. Antibiotics (Basel). 2024 Sep 18;13(9):894. doi: 10.3390/antibiotics13090894. PMID: 39335067; PMCID: PMC11428601.
22.Akarsu C, Karabulut M, Aydin H, Sahbaz NA, Dural AC, Yegul D, Peker KD, Ferahman S, Bulut S, Dönmez T, Asar S, Yasar KK, Adas GT. Association between Acute Pancreatitis and COVID-19: Could Pancreatitis Be the Missing Piece of the Puzzle about Increased Mortality Rates? J Invest Surg. 2022 Jan;35(1):119-125. doi: 10.1080/08941939.2020.1833263. Epub 2020 Nov 2. PMID: 33138658.
23.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
24.Ning F, Han X, Fan M, Tian X, Wen H, Yan X, Gao M, Li X. [Arterial partial pressure of oxygen and procalcitonin combined with ROX index predict the timing of tracheal intubation in patients with acute severe pancreatitis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Jul;35(7):752-756. Chinese. doi: 10.3760/cma.j.cn121430-20230314-00173. PMID: 37545455.
25.Capurso G, de-Madaria E. Procalcitonin-guided reduction of antibiotic use in acute pancreatitis. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):896-897. doi: 10.1016/S2468-1253(22)00231-X. Epub 2022 Jul 19. PMID: 35863359.
26.Li B, Wu W, Liu A, Feng L, Li B, Mei Y, Tan L, Zhang C, Tian Y. Establishment and Validation of a Nomogram Prediction Model for the Severe Acute Pancreatitis. J Inflamm Res. 2023 Jul 8;16:2831-2843. doi: 10.2147/JIR.S416411. PMID: 37449283; PMCID: PMC10337691.
27.Ramirez-Gonzalez LR, Ordonez-Forestiery LR, Garcia A, Iniguez-Martin-Del-Campo MC, Llamas-Hernandez FD, Morfin-Meza KD, Gonzalez-Munoz SE, Capetillo-Texson CE, Gomez-Sierra JP, Suarez-Carreon LO, Cervantes-Guevara G, Cervantes-Perez E, Ramirez-Ochoa S, Alvarez-Villasenor AS, Cortes-Flores AO, Gonzalez-Ojeda A, Fuentes-Orozco C. Procalcitonin as a Predictor of Mortality in Patients With Severe Acute Pancreatitis. Gastroenterology Res. 2025 Apr;18(2):56-62. doi: 10.14740/gr2029. Epub 2025 Apr 20. PMID: 40322192; PMCID: PMC12045753.
28.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
29.Chen L, Jiang J. The Diagnostic Value of Procalcitonin in Patients with Severe Acute Pancreatitis: A Meta-Analysis. Turk J Gastroenterol. 2022 Sep;33(9):722-730. doi: 10.5152/tjg.2022.22098. PMID: 36134549; PMCID: PMC9524488.
30.Wollny T, Wątek M, Wnorowska U, Piktel E, Góźdź S, Kurek K, Wolak P, Król G, Żendzian-Piotrowska M, Bucki R. Hypogelsolinemia and Decrease in Blood Plasma Sphingosine-1-Phosphate in Patients Diagnosed with Severe Acute Pancreatitis. Dig Dis Sci. 2022 Feb;67(2):536-545. doi: 10.1007/s10620-021-06865-y. Epub 2021 Feb 23. PMID: 33620599; PMCID: PMC8885474.
31.Lin C, Li J, Liu B, Hong X, Luo T, Ye J, Yu Y, Peng X, Gou S, Tang H, Yuan T, Luo J, Yang M, Feng B, Zhao Z, Ning C, Sun Z, Zhu S, Chen L, Shen D, Huang G. Metagenomic next-generation sequencing, instead of procalcitonin, could guide antibiotic usage in patients with febrile acute necrotizing pancreatitis: a multicenter, prospective cohort study. Int J Surg. 2024 May 1;110(5):2721-2729. doi: 10.1097/JS9.0000000000001162. PMID: 38348834; PMCID: PMC11093443.
32.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
33.Li X, Zhang Y, Wang W, Meng Y, Chen H, Chu G, Li H, Qi X. An inflammation-based model for identifying severe acute pancreatitis: a single-center retrospective study. BMC Gastroenterol. 2024 Feb 5;24(1):63. doi: 10.1186/s12876-024-03148-4. PMID: 38317108; PMCID: PMC10840143.
34.Kong D, Lei Z, Wang Z, Yu M, Li J, Chai W, Zhao X. A novel HCP (heparin-binding protein-C reactive protein-procalcitonin) inflammatory composite model can predict severe acute pancreatitis. Sci Rep. 2023 Jun 9;13(1):9440. doi: 10.1038/s41598-023-36552-z. PMID: 37296194; PMCID: PMC10256784.
35.Liu D, Ding Y, Wang Y, Huang B, Li F, Cao F, Li J. Clinical Characteristics and Outcomes of Hypertriglyceridemic Acute Pancreatitis Concomitant with Diabetic Ketoacidosis. Dig Dis Sci. 2025 Jul 29. doi: 10.1007/s10620-025-09246-x. Epub ahead of print. PMID: 40728594.
36.Zhang H, Li L, Wu J, Xu W, Wu J. Enteral Nutrition Preparations for Blood Glucose Variability and Prognosis for Severe Acute Pancreatitis With Stress Hyperglycemia. Altern Ther Health Med. 2023 Jan;29(1):163-169. PMID: 36074968.
37.Yu Z, Ni Q, Zhang P, Jia H, Yang F, Gao H, Zhu H, Liu F, Zhou X, Chang H, Lu J. Clinical utility of the pancreatitis activity scoring system in severe acute pancreatitis. Front Physiol. 2022 Aug 22;13:935329. doi: 10.3389/fphys.2022.935329. PMID: 36072851; PMCID: PMC9441599.
Copyright (c) 2026 Naibo Yu, Ruxia Han, Menghui Chen, Xuke Li, Kangjian Wang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.